Current Gene Therapy
Title:Meet Our Frontier Section Editor
Volume: 18 Issue: 5
Author(s): Zhi-Yao He
Affiliation:
Export Options
About this article
Cite this article as:
He Zhi-Yao , Meet Our Frontier Section Editor, Current Gene Therapy 2018; 18 (5) . https://dx.doi.org/10.2174/156652321805181101095330
DOI https://dx.doi.org/10.2174/156652321805181101095330 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance
Current Medicinal Chemistry Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry Sensing, Transport and Other Potential Biomedical Applications of Pseudopeptides
Current Medicinal Chemistry Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Ovarian Toxicity of Environmental Toxicants
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Preparation, Characterization and <i>In Vitro</i> Antioxidant Potential of Boldine-phospholipid Complex
Current Drug Therapy SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines
Letters in Organic Chemistry